Log in

NASDAQ:EXAS - EXACT Sciences Stock Price, Forecast & News

$89.57
-2.61 (-2.83 %)
(As of 01/24/2020 04:00 PM ET)
Today's Range
$87.70
Now: $89.57
$92.73
50-Day Range
$84.37
MA: $92.89
$104.44
52-Week Range
$75.35
Now: $89.57
$123.99
Volume1.93 million shs
Average Volume2.33 million shs
Market Capitalization$11.63 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.35
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXAS
CUSIP30063P10
Phone608-535-8815

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$454.46 million
Book Value$5.54 per share

Profitability

Net Income$-175,150,000.00

Miscellaneous

Employees1,977
Market Cap$11.63 billion
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.


EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings data on Tuesday, October, 29th. The medical research company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.41) by $0.10. The medical research company earned $218.81 million during the quarter, compared to analysts' expectations of $216.14 million. EXACT Sciences had a negative net margin of 29.83% and a negative return on equity of 29.06%. The firm's revenue for the quarter was up 85.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.37) EPS. View EXACT Sciences' Earnings History.

When is EXACT Sciences' next earnings date?

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for EXACT Sciences.

What guidance has EXACT Sciences issued on next quarter's earnings?

EXACT Sciences issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $294-296 million, compared to the consensus revenue estimate of $265.89 million.

What price target have analysts set for EXAS?

16 brokerages have issued 12 month price objectives for EXACT Sciences' shares. Their forecasts range from $102.00 to $143.00. On average, they expect EXACT Sciences' stock price to reach $122.93 in the next year. This suggests a possible upside of 37.2% from the stock's current price. View Analyst Price Targets for EXACT Sciences.

What is the consensus analysts' recommendation for EXACT Sciences?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences.

What are Wall Street analysts saying about EXACT Sciences stock?

Here are some recent quotes from research analysts about EXACT Sciences stock:
  • 1. According to Zacks Investment Research, "Over the past year, Exact Science has been outperforming its industry. The company has demonstrated strength across its entire business, driven by impressive performances with its Cologuard business. It is also progressing well in terms of its three priorities in 2019. We are currently looking forward to Exact Science’s recently-closed merger with advanced molecular diagnostics company Genomic Health. The company exhibited an impressive performance with better-than-expected earnings results in the third quarter of 2019. On the flip side, escalating expenses are putting pressure on operating margin. Sole reliance on Cologuard and competitive headwinds persist as major downsides." (1/21/2020)
  • 2. Canaccord Genuity analysts commented, "We are buyers of EXAS following the unusual 10% weakness in shares today, which we believe were part of the overall selloff today in diagnostics (and software stocks), where much of the alpha in the overall stock market has come from; and what we believe is likely certain funds pressuring EXAS following a cost effectiveness study published last week, but got a lot more attention today on the Street. We believe this is a buy-on- weakness opportunity on shares of EXAS given a handful of deep flaws used in the study." (9/10/2019)

Has EXACT Sciences been receiving favorable news coverage?

News articles about EXAS stock have trended negative on Saturday, InfoTrie reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. EXACT Sciences earned a coverage optimism score of -2.7 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for EXACT Sciences.

Are investors shorting EXACT Sciences?

EXACT Sciences saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 14,380,000 shares, an increase of 11.5% from the December 15th total of 12,900,000 shares. Based on an average trading volume of 2,070,000 shares, the days-to-cover ratio is currently 6.9 days. Approximately 11.2% of the company's shares are short sold. View EXACT Sciences' Current Options Chain.

Who are some of EXACT Sciences' key competitors?

What other stocks do shareholders of EXACT Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other EXACT Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Aduro BioTech (ADRO), salesforce.com (CRM), Paypal (PYPL), Advanced Micro Devices (AMD), AT&T (T) and Netflix (NFLX).

Who are EXACT Sciences' key executives?

EXACT Sciences' management team includes the folowing people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 53)
  • Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 41)
  • Mr. Graham P. Lidgard, Chief Science Officer (Age 70)
  • Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Mark Stenhouse, Pres of Cologuard (Age 52)

Who are EXACT Sciences' major shareholders?

EXACT Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Columbus Circle Investors (0.34%), KAMES CAPITAL plc (0.29%), Artemis Investment Management LLP (0.11%), Empire Life Investments Inc. (0.08%), Rhenman & Partners Asset Management AB (0.08%) and United Services Automobile Association (0.03%). Company insiders that own EXACT Sciences stock include D Scott Coward, G Bradley Cole, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

Which institutional investors are selling EXACT Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, KAMES CAPITAL plc, Gateway Investment Advisers LLC, Columbus Circle Investors, IFP Advisors Inc, Meridian Wealth Management LLC, Artemis Investment Management LLP and SeaCrest Wealth Management LLC. Company insiders that have sold EXACT Sciences company stock in the last year include G Bradley Cole, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse and Scott C Johnson. View Insider Buying and Selling for EXACT Sciences.

Which institutional investors are buying EXACT Sciences stock?

EXAS stock was acquired by a variety of institutional investors in the last quarter, including Empire Life Investments Inc., United Services Automobile Association, Curbstone Financial Management Corp, American National Bank, Polianta Ltd, Grassi Investment Management, Perkins Coie Trust Co and Landsberg Bennett & Dubbaneh LLC. View Insider Buying and Selling for EXACT Sciences.

How do I buy shares of EXACT Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is EXACT Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $89.57.

How big of a company is EXACT Sciences?

EXACT Sciences has a market capitalization of $11.63 billion and generates $454.46 million in revenue each year. The medical research company earns $-175,150,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. EXACT Sciences employs 1,977 workers across the globe.View Additional Information About EXACT Sciences.

What is EXACT Sciences' official website?

The official website for EXACT Sciences is http://www.exactsciences.com/.

How can I contact EXACT Sciences?

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815.


MarketBeat Community Rating for EXACT Sciences (NASDAQ EXAS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  828 (Vote Outperform)
Underperform Votes:  513 (Vote Underperform)
Total Votes:  1,341
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/25/2020 by MarketBeat.com Staff

Featured Article: What is Cost of Debt?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel